Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Update: Vaccine Developers Search For Exposed Patients, Celltrion's Infliximab Shows Promise

Despite Hotspots, Recruitment A Major Challenge

Executive Summary

As a handful of frontrunners prepare to start Phase III trials of their COVID-19 vaccine candidates, enrolling patients who are likely to be exposed to the virus is of crucial importance.

You may also be interested in...



Moderna: Speed Of COVID-19 Vaccine Now Hinges On Enrolling The Right Patients

Recruiting the right patient population for Phase III trials of COVID-19 vaccines will be a key factor in how fast any candidate can come to market. The challenge, which will likely mean enrolling patients who often are underrepresented in trials, is keeping Moderna's Chief Medical Officer up at night. The company also talked vaccine distribution, what it feels it owes the US government for its financial support, and pricing of its potential mRNA vaccine on a recent New York Academy of Sciences webinar.

Coronavirus Update: J&J Accelerates Vaccine Study

BASF enters the lists and a new UK study, CATALYST, gets underway.

Coronavirus Update: Moderna And Pfizer Respond To Vaccine Trial Transparency Demands

Moderna led by releasing the trial protocol for its COVID-19 vaccine study, followed by Pfizer, as industry faces demands for transparency.

Topics

Related Companies

UsernamePublicRestriction

Register

ID001014

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel